US2015265583A1PendingUtilityA1

Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof

73
Assignee: FORUM PHARMACEUTICALS INCPriority: Nov 19, 2008Filed: Oct 8, 2014Published: Sep 24, 2015
Est. expiryNov 19, 2028(~2.3 yrs left)· nominal 20-yr term from priority
Inventors:Richard ChesworthGideon ShapiroGerhard Koenig
A61K 31/439A61P 25/00A61K 2121/00A61K 31/4462A61K 9/00A61K 31/4427A61K 47/00A61K 31/4406A61P 25/26
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for improving cognition comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg. 
     
     
         2 . The method of  claim 1  wherein the daily dose is 1 mg or less. 
     
     
         3 . The method of  claim 2  wherein the daily dose is 0.3 mg or less. 
     
     
         4 . A method for treating a cognitive disorder comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yObenzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg. 
     
     
         5 . The method of  claim 4  wherein the daily dose is 1 mg or less. 
     
     
         6 . The method of  claim 5  wherein the daily dose is 0.3 mg or less. 
     
     
         7 . A method for treating a disorder selected from schizophrenia, schizophreniform disorder, schizoaffective disorder, and delusional disorder comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg. 
     
     
         8 . The method of  claim 7  wherein the daily dose is 1 mg or less. 
     
     
         9 . The method of  claim 8  wherein the daily dose is 0.3 mg or less 
     
     
         10 . A method for improving one or more of: learning, delayed memory, working memory, visual learning, speed of processing, vigilance, verbal learning, visual motor function, social cognition, long term memory or executive function comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg. 
     
     
         11 . The method of  claim 10  wherein the daily dose is 1 mg or less. 
     
     
         12 . The method of  claim 11  wherein the daily dose is 0.3 mg or less. 
     
     
         13 . A method for improving executive function comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yObenzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg. 
     
     
         14 . The method of  claim 13  wherein the daily dose is 1 mg or less. 
     
     
         15 . The method of  claim 14  wherein the daily dose is 0.3 mg or less. 
     
     
         16 . A method for treating one or more symptoms of Alzheimer's disease comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg. 
     
     
         17 . The method of  claim 16  wherein the daily dose is 1 mg or less. 
     
     
         18 . The method of  claim 17  wherein the daily dose is 0.3 mg or less. 
     
     
         19 . A method for improving one or more of: visual motor skills, learning, executive function, and delayed memory in a subject, the method comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg. 
     
     
         20 . The method of  claim 19  wherein the daily dose is 1 mg or less. 
     
     
         21 . The method of  claim 20  wherein the daily dose is 0.3 mg or less. 
     
     
         22 . A method for improving one or more of: attention, learning, delayed memory, working memory, visual learning, speed of processing, vigilance, verbal learning, visual motor function, social cognition, long term memory or executive function comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg. 
     
     
         23 . The method of  claim 10  wherein the daily dose is 1 mg or less. 
     
     
         24 . The method of  claim 11  wherein the daily dose is 0.3 mg or less. 
     
     
         25 . The method of any of the forgoing claims wherein the subject is suffering from anxiety or agitation. 
     
     
         26 . A unit dose pharmaceutical composition comprising 0.3 to 3.0 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
     
     
         27 . A unit dose pharmaceutical composition comprising 0.3 to 1.5 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
     
     
         28 . A unit dose pharmaceutical composition comprising 1 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2015265583A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.